Key clinical point: Among women with BRCA1 sequence variation, magnetic resonance imaging (MRI) surveillance reduces the risk for breast cancer (BC) mortality by 80% and can be offered to those aged 30 years or older.
Major finding: After a mean follow-up of 9.2 years, 344 women developed BC and 35 died due to BC. Among women who did vs did not undergo MRI surveillance, the reduction in BC mortality risk was 80% among those with BRCA1 sequence variation (hazard ratio [HR] 0.20; P < .001) but was not significant among those with BRCA2 sequence variation.
Study details: This cohort study included 2488 women (age ≥ 30 years) with BRCA1 or BRCA2 sequence variation, of which 1756 women underwent at least one MRI screening.
Disclosures: This study was supported by the Canadian Institutes of Health Research and others. Several authors declared receiving grants or personal fees or having other ties with various sources.
Source: Lubinski J, Kotsopoulos J, Moller P, et al, for the Hereditary Breast Cancer Clinical Study Group. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024 (Feb 29). doi: 10.1001/jamaoncol.2023.6944 Source